Results 191 to 200 of about 221,511 (300)

Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics. [PDF]

open access: yesNanomaterials (Basel)
Apostolopoulou A   +5 more
europepmc   +1 more source

Localized NF‐κB Inhibition Reduces Lipid Nanoparticle‐Associated Inflammation

open access: yesAdvanced Science, EarlyView.
Lipid nanoparticles (LNPs) activate NF‐κB and provoke inflammation that limits therapeutic delivery. By encapsulating selective NF‐κB inhibitors within LNPs, localized suppression of inflammatory signaling is achieved without compromising mRNA expression.
Carolann L. Espy   +16 more
wiley   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

open access: yesAdvanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang   +10 more
wiley   +1 more source

The chaperone DNAJB6b halts amyloid formation through association with transient Aβ oligomers.

open access: yesPhys Chem Chem Phys
Getachew J   +5 more
europepmc   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

open access: yesAdvanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason   +12 more
wiley   +1 more source

Effect of Loading Strategy on Methylene Blue Encapsulation in Ethosomes: A Comparative Study of Aqueous and Ethanol Phases. [PDF]

open access: yesMethods Protoc
Yakovlev D   +7 more
europepmc   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

open access: yesAdvanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy